CSBR
Price
$8.06
Change
+$0.05 (+0.62%)
Updated
Jul 21, 04:55 PM (EDT)
Capitalization
110.75M
51 days until earnings call
PMN
Price
$1.12
Change
+$0.68 (+154.55%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
14.39M
28 days until earnings call
Interact to see
Advertisement

CSBR vs PMN

Header iconCSBR vs PMN Comparison
Open Charts CSBR vs PMNBanner chart's image
Champions Oncology
Price$8.06
Change+$0.05 (+0.62%)
Volume$200
Capitalization110.75M
ProMIS Neurosciences
Price$1.12
Change+$0.68 (+154.55%)
Volume$310.9K
Capitalization14.39M
CSBR vs PMN Comparison Chart in %
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSBR vs. PMN commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Hold and PMN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (CSBR: $8.01 vs. PMN: $0.44)
Brand notoriety: CSBR and PMN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 71% vs. PMN: 18%
Market capitalization -- CSBR: $110.75M vs. PMN: $14.39M
CSBR [@Biotechnology] is valued at $110.75M. PMN’s [@Biotechnology] market capitalization is $14.39M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 1 FA rating(s) are green whilePMN’s FA Score has 0 green FA rating(s).

  • CSBR’s FA Score: 1 green, 4 red.
  • PMN’s FA Score: 0 green, 5 red.
According to our system of comparison, CSBR is a better buy in the long-term than PMN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 6 TA indicator(s) are bullish while PMN’s TA Score has 6 bullish TA indicator(s).

  • CSBR’s TA Score: 6 bullish, 4 bearish.
  • PMN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, PMN is a better buy in the short-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а -1.11% price change this week, while PMN (@Biotechnology) price change was +12.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +15.57%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

CSBR is expected to report earnings on Jul 21, 2025.

PMN is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CSBR($111M) has a higher market cap than PMN($14.4M). CSBR has higher P/E ratio than PMN: CSBR (17.80) vs PMN (4.89). CSBR YTD gains are higher at: -6.534 vs. PMN (-53.566). CSBR has higher annual earnings (EBITDA): 8.43M vs. PMN (-933.94K). PMN has more cash in the bank: 8.4M vs. CSBR (3.2M). PMN has less debt than CSBR: PMN (4.05M) vs CSBR (6.44M). CSBR has higher revenues than PMN: CSBR (58.6M) vs PMN (0).
CSBRPMNCSBR / PMN
Capitalization111M14.4M771%
EBITDA8.43M-933.94K-902%
Gain YTD-6.534-53.56612%
P/E Ratio17.804.89364%
Revenue58.6M0-
Total Cash3.2M8.4M38%
Total Debt6.44M4.05M159%
FUNDAMENTALS RATINGS
CSBR vs PMN: Fundamental Ratings
CSBR
PMN
OUTLOOK RATING
1..100
850
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1094
PRICE GROWTH RATING
1..100
5593
P/E GROWTH RATING
1..100
7299
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CSBR's Valuation (83) in the Biotechnology industry is in the same range as PMN (94) in the null industry. This means that CSBR’s stock grew similarly to PMN’s over the last 12 months.

CSBR's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PMN (100) in the null industry. This means that CSBR’s stock grew similarly to PMN’s over the last 12 months.

CSBR's SMR Rating (10) in the Biotechnology industry is significantly better than the same rating for PMN (94) in the null industry. This means that CSBR’s stock grew significantly faster than PMN’s over the last 12 months.

CSBR's Price Growth Rating (55) in the Biotechnology industry is somewhat better than the same rating for PMN (93) in the null industry. This means that CSBR’s stock grew somewhat faster than PMN’s over the last 12 months.

CSBR's P/E Growth Rating (72) in the Biotechnology industry is in the same range as PMN (99) in the null industry. This means that CSBR’s stock grew similarly to PMN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRPMN
RSI
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bullish Trend 4 days ago
68%
Bullish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
72%
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
Bearish Trend 7 days ago
78%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
71%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BMRA3.40N/A
N/A
Biomerica
SKT31.54-0.28
-0.88%
Tanger
ARE78.17-0.72
-0.91%
Alexandria Real Estate Equities
ULBI8.69-0.14
-1.59%
Ultralife Corp
IMTX6.00-0.21
-3.38%
Immatics NV

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and LIXT have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and LIXT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
-4.19%
LIXT - CSBR
25%
Poorly correlated
+7.41%
CVAC - CSBR
25%
Poorly correlated
-0.19%
PHAT - CSBR
23%
Poorly correlated
-4.45%
PMN - CSBR
23%
Poorly correlated
-6.38%
AMGXF - CSBR
23%
Poorly correlated
N/A
More

PMN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PMN has been loosely correlated with BBIO. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then BBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMN
1D Price
Change %
PMN100%
-6.38%
BBIO - PMN
40%
Loosely correlated
-0.49%
ABOS - PMN
29%
Poorly correlated
+1.35%
GALT - PMN
25%
Poorly correlated
-3.11%
VANI - PMN
25%
Poorly correlated
-4.32%
NBY - PMN
25%
Poorly correlated
+2.00%
More